Jun. 8 at 12:25 PM
$MGTX Incyte has acquired Vega Therapeutics for ~
$2B and while not related to Meira in terms of disease, it's important to note that Vega has a single late stage asset that has projected peak annual sales in the
$500M -
$750M range.... They have no other late stage assets, no manufacturing assets, a limited patent estate, no JV's, etc.
Let that sink in relative to the totality of assets that Meira owns and the aggregate amount of peak sales potential that exists across their late stage programs.
